Astraglass Innovations, a U.S.-based manufacturer of scientific glassware, reactor systems, and bioprocess solutions, today announced that it will preview STRYDE™, its patent-pending bioprocess platform, at INTERPHEX 2026 in New York.
Designed as an optional enhancement to Astraglass reactor systems, STRYDE™ supports improved monitoring, visualization, traceability, and reduced operator intervention in bioprocess workflows. The platform is intended for customers seeking a more modern and controlled operating experience for cell culture, fermentation, and related upstream bioprocess applications.
Astraglass reactor systems are available in jacketed and non-jacketed configurations and are built to support flexibility, reliability, and ease of use in research and process environments. With STRYDE™, Astraglass is expanding beyond glass fabrication alone to offer a more integrated bioprocess solution built around its reactor platform.
Astraglass will showcase its reactor capabilities and introduce STRYDE™ to attendees at INTERPHEX 2026, where the company will highlight its broader expansion in life sciences and bioprocessing solutions.
“STRYDE™ reflects where we believe bioprocessing is headed with greater visibility, better
traceability, and a more streamlined user experience. Our goal is to combine Astraglass’s strength
in reactor design and fabrication with a modern platform that helps customers operate with more
control and less manual oversight.”
— Dr. Subu Natesan, CEO & President, Astraglass Innovations
